PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 2149029
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 2149029
Anti-Fungal Drugs Market Size, Share, Growth and Global Industry Analysis, Regional Insights and Forecast to 2026-2034
Growth Factors of antifungal drugs Market
The global antifungal drugs market size was valued at USD 17.83 billion in 2025. The market is projected to grow from USD 18.77 billion in 2026 to USD 28.35 billion by 2034, according to the report data provided. North America dominated the global market in 2025, supported by a high burden of fungal infections, advanced healthcare infrastructure, strong pharmaceutical research, and widespread availability of antifungal therapies.
Fungal infections range from superficial conditions affecting the skin, hair, and nails to severe systemic infections involving the lungs and other organs. Common conditions such as dermatophytosis, ringworm, athlete's foot, and fungal nail infections continue to generate demand for antifungal medicines. At the same time, serious infections such as candidiasis, aspergillosis, cryptococcosis, and mucormycosis are increasing the need for advanced therapeutic options.
Market Trends
Growing Use of Nanotechnology in Advanced Antifungal Formulations
The increasing prevalence of fungal diseases has encouraged pharmaceutical companies to develop improved drug-delivery systems. Nanotechnology is gaining attention for enhancing drug delivery, improving therapeutic effectiveness, and potentially addressing limitations associated with conventional antifungal formulations. Nanoemulsions and nanostructured delivery systems are being explored for conditions such as onychomycosis, oral candidiasis, and vaginal candidiasis. These developments are contributing to innovation within the antifungal drugs market.
Market Drivers
Rising Incidence of Hospital-Acquired Fungal Infections
The growing occurrence of healthcare-associated fungal infections is a major factor supporting market growth. Patients undergoing cancer treatment, transplantation, intensive care, or other procedures that weaken the immune system are particularly vulnerable to invasive fungal infections. Increasing hospital admissions and the rising population of immunocompromised patients are consequently generating sustained demand for antifungal medicines.
Expansion of Research and Development Activities
Pharmaceutical companies are increasing investments in research and clinical development to address treatment limitations, drug resistance, toxicity, and the growing complexity of invasive fungal infections. Existing therapies such as azoles, polyenes, and echinocandins remain important, while newer formulations and drug candidates are being developed to improve outcomes in difficult-to-treat infections.
Market Restraints
Adverse Effects Associated with Conventional Antifungal Drugs
Safety concerns associated with certain established antifungal medicines can restrict their use. Amphotericin B, for example, can be associated with adverse effects including nephrotoxicity, hypokalemia, and bone marrow suppression. In addition, increasing fungal resistance, availability of generic medicines, stringent regulatory requirements, patent expirations, and counterfeit products can create challenges for market expansion.
Segmentation Analysis
By Drug Type
The market is segmented into azoles, echinocandins, polyenes, and allylamines. Azoles represented the leading segment, supported by extensive clinical use and the availability of medicines such as fluconazole and ketoconazole. Echinocandins are also gaining importance because of their use in invasive systemic fungal infections. Polyenes remain important for serious infections, while allylamines are widely used for dermatological fungal conditions.
By Indication
The market is divided into dermatophytosis, aspergillosis, candidiasis, and others. Dermatophytosis held the leading position due to its widespread occurrence and high treatment demand. Candidiasis represents another important application because of the increasing incidence of healthcare-associated infections. Aspergillosis and other severe infections, including mucormycosis and fungal meningitis, are also supporting demand for advanced antifungal therapies.
By Route of Administration
The market includes oral, topical, and parenteral formulations. Topical antifungal medicines held a prominent position because of their extensive use for superficial skin and nail infections. Oral therapies are expected to experience strong demand as convenient treatment options become increasingly available, while parenteral formulations remain essential for severe and invasive fungal infections.
By Distribution Channel
Distribution channels include retail pharmacies, hospital pharmacies and stores, and online pharmacies. Hospital pharmacies represent an important channel because patients with severe fungal infections frequently require physician-supervised treatment. Retail pharmacies benefit from demand for dermatological antifungal products, while online pharmacies are gaining attention because of convenience and increasing consumer adoption of digital healthcare purchasing.
Regional Analysis
North America remained the leading regional market, valued at USD 4.61 billion in 2025. Strong healthcare infrastructure, awareness of fungal diseases, advanced treatment availability, and substantial pharmaceutical R&D activities support regional growth.
Europe held the second-largest position, supported by healthcare expenditure, established medical infrastructure, and increasing diagnosis and treatment of fungal infections.
Asia Pacific is expected to record the strongest growth during the forecast period. Rising healthcare investment, increasing fungal infection prevalence, expanding pharmaceutical activities, and government initiatives are creating significant market opportunities.
Latin America and the Middle East & Africa are expected to witness comparatively slower development, although improvements in healthcare access, disease awareness, and treatment availability could create future opportunities.
Key Industry Players
Prominent companies operating in the antifungal drugs market include Astellas Pharma Inc., Merck & Co., Inc., Pfizer Inc., Leadiant Biosciences, Inc., McKesson Medical-Surgical Inc., GlaxoSmithKline plc., Novartis AG, Bayer AG, and Abbott. These companies are focusing on product development, portfolio expansion, strategic collaborations, and clinical research to strengthen their market positions.
Investment Analysis and Opportunities
The market presents investment opportunities in novel antifungal therapies, advanced drug-delivery technologies, and treatments targeting resistant fungal infections. Companies developing formulations with improved safety, efficacy, patient convenience, and targeted delivery may benefit from increasing clinical demand. Asia Pacific also offers attractive opportunities because of expanding healthcare infrastructure and pharmaceutical manufacturing capabilities.
New Product Development
New product development is increasingly focused on overcoming the limitations of conventional antifungal medicines. Researchers are exploring nanoformulations, improved oral formulations, novel mechanisms of action, and therapies designed to address drug-resistant fungal pathogens. Such innovations can improve treatment outcomes while expanding therapeutic options for patients with severe infections.
Five Recent Developments
- April 2018: Sun Pharmaceutical Industries Ltd. launched Abzorb antifungal powder for dermatological fungal infections.
- October 2017: Mylan N.V. launched caspofungin acetate injection as a generic antifungal treatment.
- Pharmaceutical companies have continued expanding clinical research into novel therapies for invasive fungal infections.
- Drug-delivery technologies such as nanoemulsions are receiving greater attention for improving antifungal treatment.
- Strategic collaborations between pharmaceutical companies are supporting wider commercialization and regional availability of antifungal products.
Report Coverage
The antifungal drugs market report covers key market segments based on drug type, indication, route of administration, and distribution channel. It also evaluates regional market performance across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The report examines market trends, major drivers, restraints, competitive developments, product innovation, R&D activities, and emerging opportunities influencing the industry's development.
Conclusion
The global antifungal drugs market is positioned for steady expansion, increasing from USD 17.83 billion in 2025 to USD 18.77 billion in 2026 and reaching USD 28.35 billion by 2034. Rising fungal infection prevalence, hospital-acquired infections, pharmaceutical R&D, and advancements in drug-delivery technologies are expected to remain central to market development. While adverse effects, drug resistance, regulatory requirements, and treatment costs present challenges, innovation in novel formulations and therapies is creating significant opportunities for pharmaceutical companies across established and emerging markets.
Unit Value (USD billion)
Segmentation By Drug Type
- Azoles
- Echinocandins
- Polyenes
- Allylamines
By Indication
- Dermatophytosis
- Candidiasis
- Aspergillosis
- Others
By Route of Administration
- Oral
- Topical
- Parenteral
By Distribution Channel
- Hospitals & Pharmacies
- Retail Pharmacies & Drug Stores
- Online Pharmacies
By Geography
- North America (the U.S. and Canada)
- Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and the Rest of Europe)
- Asia-Pacific (Japan, China, India, Australia, Southeast Asia, and the Rest of Asia- Pacific)
- Latin America (Brazil, Mexico, and the Rest of Latin America)
- Middle East & Africa (South Africa, GCC, and the Rest of Middle East & Africa)
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
4. Key Insights
- 4.1. Key Industry Developments (Mergers, Acquisitions, and Partnerships, etc.)
- 4.2. Prevalence of Fungal Infections
- 4.3. Pipeline Analysis
- 4.4. New Product Launches
5. Global Anti-Fungal Drugs Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Key Findings / Summary
- 5.2. Market Analysis, Insights and Forecast - By Drug Type
- 5.2.1. Azoles
- 5.2.2. Echinocandins
- 5.2.3. Polyenes
- 5.2.4. Allylamines
- 5.3. Market Analysis, Insights and Forecast - By Indication
- 5.3.1. Dermatophytosis
- 5.3.2. Candidiasis
- 5.3.3. Aspergillosis
- 5.3.4. Others
- 5.4. Market Analysis, Insights and Forecast - By Route of Administration
- 5.4.1. Oral
- 5.4.2. Topical
- 5.4.3. Parenteral
- 5.5. Market Analysis, Insights and Forecast - By Distribution Channel
- 5.5.1. Hospitals Pharmacies
- 5.5.2. Retail Pharmacies & Drug Stores
- 5.5.3. Online Pharmacies
- 5.6. Market Analysis, Insights and Forecast - By Region
- 5.6.1. North America
- 5.6.2. Europe
- 5.6.3. Asia pacific
- 5.6.4. Latin America
- 5.6.5. Middle East & Africa
6. North America Anti-Fungal Drugs Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Key Findings / Summary
- 6.2. Market Analysis - By Drug Type
- 6.2.1. Azoles
- 6.2.2. Echinocandins
- 6.2.3. Polyenes
- 6.2.4. Allylamines
- 6.3. Market Analysis - By Indication
- 6.3.1. Dermatophytosis
- 6.3.2. Candidiasis
- 6.3.3. Aspergillosis
- 6.3.4. Others
- 6.4. Market Analysis - By Route of Administration
- 6.4.1. Oral
- 6.4.2. Topical
- 6.4.3. Parenteral
- 6.5. Market Analysis - By Distribution Channel
- 6.5.1. Hospitals Pharmacies
- 6.5.2. Retail Pharmacies & Drug Stores
- 6.5.3. Online Pharmacies
- 6.6. Market Analysis - By Country
- 6.6.1. U.S.
- 6.6.2. Canada
7. Europe Anti-Fungal Drugs Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Key Findings / Summary
- 7.2. Market Analysis - By Drug Type
- 7.2.1. Azoles
- 7.2.2. Echinocandins
- 7.2.3. Polyenes
- 7.2.4. Allylamines
- 7.3. Market Analysis - By Indication
- 7.3.1. Dermatophytosis
- 7.3.2. Candidiasis
- 7.3.3. Aspergillosis
- 7.3.4. Others
- 7.4. Market Analysis - By Route of Administration
- 7.4.1. Oral
- 7.4.2. Topical
- 7.4.3. Parenteral
- 7.5. Market Analysis - By Distribution Channel
- 7.5.1. Hospitals Pharmacies
- 7.5.2. Retail Pharmacies & Drug Stores
- 7.5.3. Online Pharmacies
- 7.6. Market Analysis - By Country/ sub-region
- 7.6.1. U.K.
- 7.6.2. Germany
- 7.6.3. France
- 7.6.4. Spain
- 7.6.5. Italy
- 7.6.6. Scandinavia
- 7.6.7. Rest of Europe
8. Asia pacific Anti-Fungal Drugs Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Key Findings / Summary
- 8.2. Market Analysis - By Drug Type
- 8.2.1. Azoles
- 8.2.2. Echinocandins
- 8.2.3. Polyenes
- 8.2.4. Allylamines
- 8.3. Market Analysis - By Indication
- 8.3.1. Dermatophytosis
- 8.3.2. Candidiasis
- 8.3.3. Aspergillosis
- 8.3.4. Others
- 8.4. Market Analysis - By Route of Administration
- 8.4.1. Oral
- 8.4.2. Topical
- 8.4.3. Parenteral
- 8.5. Market Analysis - By Distribution Channel
- 8.5.1. Hospitals Pharmacies
- 8.5.2. Retail Pharmacies & Drug Stores
- 8.5.3. Online Pharmacies
- 8.6. Market Analysis - By Country/ sub-region
- 8.6.1. Japan
- 8.6.2. China
- 8.6.3. India
- 8.6.4. Australia
- 8.6.5. Southeast Asia
- 8.6.6. Rest of Asia Pacific
9. Latin America Anti-Fungal Drugs Market Analysis, Insights and Forecast, 2021-2034
- 9.1. Key Findings / Summary
- 9.2. Market Analysis - By Drug Type
- 9.2.1. Azoles
- 9.2.2. Echinocandins
- 9.2.3. Polyenes
- 9.2.4. Allylamines
- 9.3. Market Analysis - By Indication
- 9.3.1. Dermatophytosis
- 9.3.2. Candidiasis
- 9.3.3. Aspergillosis
- 9.3.4. Others
- 9.4. Market Analysis - By Route of Administration
- 9.4.1. Oral
- 9.4.2. Topical
- 9.4.3. Parenteral
- 9.5. Market Analysis - By Distribution Channel
- 9.5.1. Hospitals Pharmacies
- 9.5.2. Retail Pharmacies & Drug Stores
- 9.5.3. Online Pharmacies
- 9.6. Market Analysis - By Country/ sub-region
- 9.6.1. Brazil
- 9.6.2. Mexico
- 9.6.3. Rest of Latin America
10. Middle East & Africa Anti-Fungal Drugs Market Analysis, Insights and Forecast, 2021-2034
- 10.1. Key Findings / Summary
- 10.2. Market Analysis - By Drug Type
- 10.2.1. Azoles
- 10.2.2. Echinocandins
- 10.2.3. Polyenes
- 10.2.4. Allylamines
- 10.3. Market Analysis - By Indication
- 10.3.1. Dermatophytosis
- 10.3.2. Candidiasis
- 10.3.3. Aspergillosis
- 10.3.4. Others
- 10.4. Market Analysis - By Route of Administration
- 10.4.1. Oral
- 10.4.2. Topical
- 10.4.3. Parenteral
- 10.5. Market Analysis - By Distribution Channel
- 10.5.1. Hospitals Pharmacies
- 10.5.2. Retail Pharmacies & Drug Stores
- 10.5.3. Online Pharmacies
- 10.6. Market Analysis - By Country/ sub-region
- 10.6.1. GCC Countries
- 10.6.2. South Africa
- 10.6.3. Rest of Middle East & Africa
11. Competitive Analysis
- 11.1. Key Industry Developments
- 11.2. Global Market Share Analysis (2025)
- 11.3. Competition Dashboard
- 11.4. Comparative Analysis - Major Players
- 11.5. Company Profiles
- 11.5.1. Astellas Pharma Inc.
- 11.5.1.1. Overview,
- 11.5.1.2. Products & services,
- 11.5.1.3. SWOT analysis,
- 11.5.1.4. Recent developments,
- 11.5.1.5. strategies,
- 11.5.1.6. financials (based on availability)
- 11.5.2. Merck & Co., Inc.
- 11.5.2.1. Overview,
- 11.5.2.2. Products & services,
- 11.5.2.3. SWOT analysis,
- 11.5.2.4. Recent developments,
- 11.5.2.5. strategies,
- 11.5.2.6. financials (based on availability)
- 11.5.3. Pfizer Inc
- 11.5.3.1. Overview,
- 11.5.3.2. Products & services,
- 11.5.3.3. SWOT analysis,
- 11.5.3.4. Recent developments,
- 11.5.3.5. strategies,
- 11.5.3.6. financials (based on availability)
- 11.5.4. Leadiant Biosciences, Inc.
- 11.5.4.1. Overview,
- 11.5.4.2. Products & services,
- 11.5.4.3. SWOT analysis,
- 11.5.4.4. Recent developments,
- 11.5.4.5. strategies,
- 11.5.4.6. financials (based on availability)
- 11.5.5. McKesson Medical-Surgical Inc
- 11.5.5.1. Overview,
- 11.5.5.2. Products & services,
- 11.5.5.3. SWOT analysis,
- 11.5.5.4. Recent developments,
- 11.5.5.5. strategies,
- 11.5.5.6. financials (based on availability)
- 11.5.6. GlaxoSmithKline plc.
- 11.5.6.1. Overview,
- 11.5.6.2. Products & services,
- 11.5.6.3. SWOT analysis,
- 11.5.6.4. Recent developments,
- 11.5.6.5. strategies,
- 11.5.6.6. financials (based on availability)
- 11.5.7. Novartis AG
- 11.5.7.1. Overview,
- 11.5.7.2. Products & services,
- 11.5.7.3. SWOT analysis,
- 11.5.7.4. Recent developments,
- 11.5.7.5. strategies,
- 11.5.7.6. financials (based on availability)
- 11.5.8. Bayer AG
- 11.5.8.1. Overview,
- 11.5.8.2. Products & services,
- 11.5.8.3. SWOT analysis,
- 11.5.8.4. Recent developments,
- 11.5.8.5. strategies,
- 11.5.8.6. financials (based on availability)
- 11.5.9. Abbott
- 11.5.9.1. Overview,
- 11.5.9.2. Products & services,
- 11.5.9.3. SWOT analysis,
- 11.5.9.4. Recent developments,
- 11.5.9.5. strategies,
- 11.5.9.6. financials (based on availability)
- 11.5.10. Other Prominent Players
- 11.5.10.1. Overview,
- 11.5.10.2. Products & services,
- 11.5.10.3. SWOT analysis,
- 11.5.10.4. Recent developments,
- 11.5.10.5. strategies,
- 11.5.10.6. financials (based on availability)
- 11.5.1. Astellas Pharma Inc.
12. Strategic Recommendations
List of Tables
- Table 1: Global Anti-Fungal Drugs Market Revenue (US$ Bn) Forecast, by Drug Type, 2021-2034
- Table 2: Global Anti-Fungal Drugs Market Revenue (US$ Bn) Forecast, by Indication, 2021-2034
- Table 3: Global Anti-Fungal Drugs Market Revenue (US$ Bn) Forecast, by Route of Administration, 2021-2034
- Table 4: Global Anti-Fungal Drugs Market Revenue (US$ Bn) Forecast, by Distribution Channel, 2021-2034
- Table 5: Global Anti-Fungal Drugs Market Revenue (US$ Bn) Forecast, by Region, 2021-2034
- Table 6: North America Anti-Fungal Drugs Market Revenue (US$ Bn) Forecast, by Drug Type, 2021-2034
- Table 7: North America Anti-Fungal Drugs Market Revenue (US$ Bn) Forecast, by Indication, 2021-2034
- Table 8: North America Anti-Fungal Drugs Market Revenue (US$ Bn) Forecast, by Route of Administration, 2021-2034
- Table 9: North America Anti-Fungal Drugs Market Revenue (US$ Bn) Forecast, by Distribution Channel, 2021-2034
- Table 10: North America Anti-Fungal Drugs Market Revenue (US$ Bn) Forecast, By Country, 2021-2034
- Table 11: Europe Anti-Fungal Drugs Market Revenue (US$ Bn) Forecast, by Drug Type, 2021-2034
- Table 12: Europe Anti-Fungal Drugs Market Revenue (US$ Bn) Forecast, by Indication, 2021-2034
- Table 13: Europe Anti-Fungal Drugs Market Revenue (US$ Bn) Forecast, by Route of Administration, 2021-2034
- Table 14: Europe Anti-Fungal Drugs Market Revenue (US$ Bn) Forecast, by Distribution Channel, 2021-2034
- Table 15: Europe Anti-Fungal Drugs Market Revenue (US$ Bn) Forecast, By Country/ Sub-region, 2021-2034
- Table 16: Asia Pacific Anti-Fungal Drugs Market Revenue (US$ Bn) Forecast, by Drug Type, 2021-2034
- Table 17: Asia Pacific Anti-Fungal Drugs Market Revenue (US$ Bn) Forecast, by Indication, 2021-2034
- Table 18: Asia Pacific Anti-Fungal Drugs Market Revenue (US$ Bn) Forecast, by Route of Administration, 2021-2034
- Table 19: Asia Pacific Anti-Fungal Drugs Market Revenue (US$ Bn) Forecast, by Distribution Channel, 2021-2034
- Table 20: Asia Pacific Anti-Fungal Drugs Market Revenue (US$ Bn) Forecast, By Country/ Sub-region, 2021-2034
- Table 21: Latin America Anti-Fungal Drugs Market Revenue (US$ Bn) Forecast, by Drug Type, 2021-2034
- Table 22: Latin America Anti-Fungal Drugs Market Revenue (US$ Bn) Forecast, by Indication, 2021-2034
- Table 23: Latin America Anti-Fungal Drugs Market Revenue (US$ Bn) Forecast, by Route of Administration, 2021-2034
- Table 24: Latin America Anti-Fungal Drugs Market Revenue (US$ Bn) Forecast, by Distribution Channel, 2021-2034
- Table 25: Latin America Anti-Fungal Drugs Market Revenue (US$ Bn) Forecast, By Country/ Sub-region, 2021-2034
- Table 26: Middle East & Africa Anti-Fungal Drugs Market Revenue (US$ Bn) Forecast, by Drug Type, 2021-2034
- Table 27: Middle East & Africa Anti-Fungal Drugs Market Revenue (US$ Bn) Forecast, by Indication, 2021-2034
- Table 28: Middle East & Africa Anti-Fungal Drugs Market Revenue (US$ Bn) Forecast, by Route of Administration, 2021-2034
- Table 29: Middle East & Africa Anti-Fungal Drugs Market Revenue (US$ Bn) Forecast, by Distribution Channel, 2021-2034
- Table 30: Middle East & Africa Anti-Fungal Drugs Market Revenue (US$ Bn) Forecast, By Country/ Sub-region, 2021-2034
List of Figures
- Figure 1: Global Anti-Fungal Drugs Market Revenue Breakdown (US$ Bn, %) by Region, 2025 & 2034
- Figure 2: Global Anti-Fungal Drugs Market Value Share (%), by Drug Type, 2025 & 2034
- Figure 3: Global Anti-Fungal Drugs Market Forecast (US$ Bn), by Azoles, 2021-2034
- Figure 4: Global Anti-Fungal Drugs Market Forecast (US$ Bn), by Echinocandins, 2021-2034
- Figure 5: Global Anti-Fungal Drugs Market Forecast (US$ Bn), by Polyenes, 2021-2034
- Figure 6: Global Anti-Fungal Drugs Market Forecast (US$ Bn), by Allylamines, 2021-2034
- Figure 7: Global Anti-Fungal Drugs Market Value Share (%), by Indication, 2025 & 2034
- Figure 8: Global Anti-Fungal Drugs Market Forecast (US$ Bn), by Dermatophytosis, 2021-2034
- Figure 9: Global Anti-Fungal Drugs Market Forecast (US$ Bn), by Candidiasis, 2021-2034
- Figure 10: Global Anti-Fungal Drugs Market Forecast (US$ Bn), by Aspergillosis, 2021-2034
- Figure 11: Global Anti-Fungal Drugs Market Forecast (US$ Bn), by Others, 2021-2034
- Figure 12: Global Anti-Fungal Drugs Market Value Share (%), by Route of Administration, 2025 & 2034
- Figure 13: Global Anti-Fungal Drugs Market Forecast (US$ Bn), by Oral, 2021-2034
- Figure 14: Global Anti-Fungal Drugs Market Forecast (US$ Bn), by Topical, 2021-2034
- Figure 15: Global Anti-Fungal Drugs Market Forecast (US$ Bn), by Parenteral, 2021-2034
- Figure 16: Global Anti-Fungal Drugs Market Value Share (%), by Distribution Channel, 2025 & 2034
- Figure 17: Global Anti-Fungal Drugs Market Forecast (US$ Bn), by Hospitals Pharmacies, 2021-2034
- Figure 18: Global Anti-Fungal Drugs Market Forecast (US$ Bn), by Retail Pharmacies & Drug Stores, 2021-2034
- Figure 19: Global Anti-Fungal Drugs Market Forecast (US$ Bn), by Online Pharmacies, 2021-2034
- Figure 20: Global Anti-Fungal Drugs Market Value (US$ Bn), by Region, 2025 & 2034
- Figure 21: North America Anti-Fungal Drugs Market Value (US$ Bn), by Drug Type, 2025 & 2034
- Figure 22: North America Anti-Fungal Drugs Market Value Share (%), by Drug Type, 2025
- Figure 23: North America Anti-Fungal Drugs Market Value (US$ Bn), by Indication, 2025 & 2034
- Figure 24: North America Anti-Fungal Drugs Market Value Share (%), by Indication, 2025
- Figure 25: North America Anti-Fungal Drugs Market Value (US$ Bn), by Route of Administration, 2025 & 2034
- Figure 26: North America Anti-Fungal Drugs Market Value Share (%), by Route of Administration, 2025
- Figure 27: North America Anti-Fungal Drugs Market Value (US$ Bn), by Distribution Channel, 2025 & 2034
- Figure 28: North America Anti-Fungal Drugs Market Value Share (%), by Distribution Channel, 2025
- Figure 29: North America Anti-Fungal Drugs Market Value (US$ Bn), By Country, 2025 & 2034
- Figure 30: North America Anti-Fungal Drugs Market Value Share (%), By Country, 2025
- Figure 31: Europe Anti-Fungal Drugs Market Value (US$ Bn), by Drug Type, 2025 & 2034
- Figure 32: Europe Anti-Fungal Drugs Market Value Share (%), by Drug Type, 2025
- Figure 33: Europe Anti-Fungal Drugs Market Value (US$ Bn), by Indication, 2025 & 2034
- Figure 34: Europe Anti-Fungal Drugs Market Value Share (%), by Indication, 2025
- Figure 35: Europe Anti-Fungal Drugs Market Value (US$ Bn), by Route of Administration, 2025 & 2034
- Figure 36: Europe Anti-Fungal Drugs Market Value Share (%), by Route of Administration, 2025
- Figure 37: Europe Anti-Fungal Drugs Market Value (US$ Bn), by Distribution Channel, 2025 & 2034
- Figure 38: Europe Anti-Fungal Drugs Market Value Share (%), by Distribution Channel, 2025
- Figure 39: Europe Anti-Fungal Drugs Market Value (US$ Bn), By Country/ Sub-region, 2025 & 2034
- Figure 40: Europe Anti-Fungal Drugs Market Value Share (%), By Country/ Sub-region, 2025
- Figure 41: Asia Pacific Anti-Fungal Drugs Market Value (US$ Bn), by Drug Type, 2025 & 2034
- Figure 42: Asia Pacific Anti-Fungal Drugs Market Value Share (%), by Drug Type, 2025
- Figure 43: Asia Pacific Anti-Fungal Drugs Market Value (US$ Bn), by Indication, 2025 & 2034
- Figure 44: Asia Pacific Anti-Fungal Drugs Market Value Share (%), by Indication, 2025
- Figure 45: Asia Pacific Anti-Fungal Drugs Market Value (US$ Bn), by Route of Administration, 2025 & 2034
- Figure 46: Asia Pacific Anti-Fungal Drugs Market Value Share (%), by Route of Administration, 2025
- Figure 47: Asia Pacific Anti-Fungal Drugs Market Value (US$ Bn), by Distribution Channel, 2025 & 2034
- Figure 48: Asia Pacific Anti-Fungal Drugs Market Value Share (%), by Distribution Channel, 2025
- Figure 49: Asia Pacific Anti-Fungal Drugs Market Value (US$ Bn), By Country/ Sub-region, 2025 & 2034
- Figure 50: Asia Pacific Anti-Fungal Drugs Market Value Share (%), By Country/ Sub-region, 2025
- Figure 51: Latin America Anti-Fungal Drugs Market Value (US$ Bn), by Drug Type, 2025 & 2034
- Figure 52: Latin America Anti-Fungal Drugs Market Value Share (%), by Drug Type, 2025
- Figure 53: Latin America Anti-Fungal Drugs Market Value (US$ Bn), by Indication, 2025 & 2034
- Figure 54: Latin America Anti-Fungal Drugs Market Value Share (%), by Indication, 2025
- Figure 55: Latin America Anti-Fungal Drugs Market Value (US$ Bn), by Route of Administration, 2025 & 2034
- Figure 56: Latin America Anti-Fungal Drugs Market Value Share (%), by Route of Administration, 2025
- Figure 57: Latin America Anti-Fungal Drugs Market Value (US$ Bn), by Distribution Channel, 2025 & 2034
- Figure 58: Latin America Anti-Fungal Drugs Market Value Share (%), by Distribution Channel, 2025
- Figure 59: Latin America Anti-Fungal Drugs Market Value (US$ Bn), By Country/ Sub-region, 2025 & 2034
- Figure 60: Latin America Anti-Fungal Drugs Market Value Share (%), By Country/ Sub-region, 2025
- Figure 61: Middle East & Africa Anti-Fungal Drugs Market Value (US$ Bn), by Drug Type, 2025 & 2034
- Figure 62: Middle East & Africa Anti-Fungal Drugs Market Value Share (%), by Drug Type, 2025
- Figure 63: Middle East & Africa Anti-Fungal Drugs Market Value (US$ Bn), by Indication, 2025 & 2034
- Figure 64: Middle East & Africa Anti-Fungal Drugs Market Value Share (%), by Indication, 2025
- Figure 65: Middle East & Africa Anti-Fungal Drugs Market Value (US$ Bn), by Route of Administration, 2025 & 2034
- Figure 66: Middle East & Africa Anti-Fungal Drugs Market Value Share (%), by Route of Administration, 2025
- Figure 67: Middle East & Africa Anti-Fungal Drugs Market Value (US$ Bn), by Distribution Channel, 2025 & 2034
- Figure 68: Middle East & Africa Anti-Fungal Drugs Market Value Share (%), by Distribution Channel, 2025
- Figure 69: Middle East & Africa Anti-Fungal Drugs Market Value (US$ Bn), By Country/ Sub-region, 2025 & 2034
- Figure 70: Middle East & Africa Anti-Fungal Drugs Market Value Share (%), By Country/ Sub-region, 2025
- Figure 71: Global Anti-Fungal Drugs Market Share (%), By Company, 2025
